VRTX

Vertex Pharmaceuticals
D

VRTX

446.43
USD
-0.22
(-0.05%)
مفتوح الان
حجم التداول
23,110
الربح لكل سهم
18
العائد الربحي
-
P/E
-117
حجم السوق
114,701,031,545
الأفكار والتحليلات
هشام منسي
هشام منسي
منذ 9 أشهر
buy
2024-08-22 05:31
VRTX Chart
المزيد
أصول ذات صلة
ABBV
ABBV
1.020
(0.54%)
188.150 USD
AMGN
AMGN
-1.73
(-0.60%)
287.55 USD
BIIB
BIIB
0.230
(0.17%)
132.130 USD
BMRN
BMRN
-0.470
(-0.83%)
56.310 USD
GILD
GILD
-0.340
(-0.31%)
108.990 USD
INCY
INCY
0.550
(0.82%)
67.680 USD
LLY
LLY
17.64
(2.35%)
767.30 USD
REGN
REGN
-3.92
(-0.80%)
484.07 USD
المزيد
الأخبار المقالات

العنوان: Vertex Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.